Search clinical trials for: Copanlisib (BAY80-6946)

Total 528 results

Bayer

Completed

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Lymphoma Non-Hodgkin

Japan
Bayer

Completed

Copanlisib Pharmacodynamic Study

Non Hodgkin Lymphoma

Belgium, France, United Kingdom
Bayer

Completed

Copanlisib Mass Balance Study

Healthy Volunteers

Netherlands
Bayer

Active, not recruiting

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Taiwan
Bayer

No longer available

Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors

Cancer

Brazil, Hong Kong, Hungary, Malaysia, Poland, Romania, Russian Federation, Taiwan, Ukraine, Ireland, Chile
Bayer

Completed

Study of Copanlisib in Hepatic or Renal Impairment

Hepatic Insufficiency, Renal Insufficiency

Germany, Romania
Bayer

Completed

Copanlisib Chinese PK Study

Lymphoma, Non-Hodgkin

China
Bayer

Completed

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)

Advanced or Metastatic Solid Tumor

United States, Spain, Korea, Republic of, Belgium, Singapore, Germany
Bayer

Terminated

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Lymphoma, Mantle-Cell

United States
Bayer

Completed

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse, Large B-Cell, Lymphoma

Belgium, France, Canada, Korea, Republic of, Australia, Germany, United Kingdom, Italy, Denmark, Singapore
Bayer

Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Hong Kong, Turkey, Russian Federation, Singapore, United States, Canada, Germany, Australia, New Zealand, Finland, Austria, United Kingdom, Bulgaria, Hungary, Italy, Israel, Korea, Republic of, Poland, Port... and more
Bayer

Completed

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

Healthy Volunteers

United States
Cancer Trials Ireland

Completed

Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (Panther)

HER2 Positive Breast Cancer

Ireland
Bayer

Completed

Japanese BAY80-6946 Monotherapy Phase I Study

Neoplasms

Japan
NRG Oncology
National Cancer Institute (NCI)

Completed

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid Adenocarcinoma

United States
Bayer

Active, not recruiting

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)

Lymphoma,Non-Hodgkin

China, Hong Kong, Spain, Taiwan, Turkey, Japan, Russian Federation, Singapore, France, Austria, Bulgaria, Korea, Republic of, Malaysia, Thailand, United States, Germany, Hungary, Italy, Philippines, Romania, Poland, Portugal, Mexico, ... and more
Bayer

Completed

Phase III Copanlisib in Rituximab-refractory iNHL (CHRONOS-2)

Lymphoma, Non-Hodgkin

Taiwan, Russian Federation, Brazil, Bulgaria, Korea, Republic of, Poland, Italy, Greece, Turkey, South Africa
M.D. Anderson Cancer Center

Withdrawn

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone
UNICANCER

Terminated

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

Carcinoma, Squamous Cell of Head and Neck

France
Bayer

Completed

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Neoplasms

United States, Germany, Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Malignant Solid Neoplasm

United States
Columbia University
Bayer

Withdrawn

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Lymphoma, T-Cell
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Bayer

Active, not recruiting

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Colon Cancer | Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer

United States
Bayer

Completed

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Neoplasms

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Bayer

Completed

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Neoplasms

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Richter Syndrome | Indolent Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Withdrawn

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
Dorothy Sipkins, MD, PhD
Bayer

Terminated

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Leukemia, Acute Lymphocytic

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

United States
Bayer

Terminated

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Relapsed or Refractory Solid Tumors or Lymphoma in Children

United States
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Cholangiocarcinoma | Gastrointestinal Tumor | Gall Bladder Carcinoma | Biliary Carcinoma

United States
Columbia University
Bayer

Active, not recruiting

Study of Copanlisib and Ketogenic Diet

Follicular Lymphoma | Endometrial Cancer

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Withdrawn

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7
Jonsson Comprehensive Cancer Center
Bayer; Translational Research in Oncology-U.S. Inc. (TRIO-US)

Terminated

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Stage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative and other conditions

United States
Cancer Trials Ireland

Terminated

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (Panthera)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Cancer

Ireland, Spain
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer

Prostate Cancer

United States
Swiss Group for Clinical Cancer Research

Terminated

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Non-Hodgkin Lymphoma

Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

Italy
Dana-Farber Cancer Institute
Bayer; AbbVie

Active, not recruiting

Copanlisib Plus Venetoclax in R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
Bayer

Completed

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Medical Oncology

Canada, United States
Bayer

Terminated

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)

Lymphoma, Non-Hodgkin

United States, Hungary, China, Belgium, Korea, Republic of, France, Australia, Russian Federation, Taiwan, Denmark, Japan, United Kingdom, Spain, South Africa, Turkey, Romania, Singapore, Israel, Ireland, Canada, Poland, Greece, Cze... and more
VA Office of Research and Development
Bayer

Not yet recruiting

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Advanced Urothelial Carcinoma

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark

Search clinical trials for: Copanlisib (BAY80-6946)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations